BR112023000588A2 - Derivados de piridazina como inibidores de alk5 e/ou alk4 - Google Patents
Derivados de piridazina como inibidores de alk5 e/ou alk4Info
- Publication number
- BR112023000588A2 BR112023000588A2 BR112023000588A BR112023000588A BR112023000588A2 BR 112023000588 A2 BR112023000588 A2 BR 112023000588A2 BR 112023000588 A BR112023000588 A BR 112023000588A BR 112023000588 A BR112023000588 A BR 112023000588A BR 112023000588 A2 BR112023000588 A2 BR 112023000588A2
- Authority
- BR
- Brazil
- Prior art keywords
- alk5
- pyridazine derivatives
- compounds
- alk4 inhibitors
- present
- Prior art date
Links
- 102100034134 Activin receptor type-1B Human genes 0.000 title abstract 2
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical class C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108010092867 Transforming Growth Factor beta Receptors Proteins 0.000 abstract 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
DERIVADOS DE PIRIDAZINA COMO INIBIDORES DE ALK5 E/OU ALK4. A presente invenção refere-se a um composto de fórmula geral (I) que inibe o receptor do fator de crescimento transformador-Beta (TGF-Beta) tipo I (ALK5), métodos de preparação de tais compostos, composições farmacêuticas que os contêm e uso terapêutico dos mesmos. Os compostos da presente invenção são úteis no tratamento de doenças ou condições associadas a uma desregulação da via de sinalização de ALK5 em um mamífero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20185890 | 2020-07-15 | ||
| PCT/EP2021/069649 WO2022013307A1 (en) | 2020-07-15 | 2021-07-14 | Pyridazinyl amino derivatives as alk5 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112023000588A2 true BR112023000588A2 (pt) | 2023-01-31 |
| BR112023000588A8 BR112023000588A8 (pt) | 2023-05-09 |
Family
ID=71620257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023000588A BR112023000588A8 (pt) | 2020-07-15 | 2021-07-14 | Derivados de piridazinil amino como inibidores de alk5 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240018122A1 (pt) |
| EP (1) | EP4182308A1 (pt) |
| JP (1) | JP2023533849A (pt) |
| KR (1) | KR20230051500A (pt) |
| CN (1) | CN116096719A (pt) |
| AR (1) | AR122986A1 (pt) |
| AU (1) | AU2021307559A1 (pt) |
| BR (1) | BR112023000588A8 (pt) |
| CA (1) | CA3184990A1 (pt) |
| MX (1) | MX2023000521A (pt) |
| TW (1) | TW202216677A (pt) |
| WO (1) | WO2022013307A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023043050A (ja) * | 2021-09-15 | 2023-03-28 | 株式会社東芝 | 新規アミン化合物、酸性ガス吸収剤、酸性ガスの除去方法及び酸性ガス除去 |
| CN114957331A (zh) * | 2022-04-22 | 2022-08-30 | 北京康辰药业股份有限公司 | 磷酸酯取代的环丙酰胺衍生喹唑啉类化合物的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002541253A (ja) | 1999-04-09 | 2002-12-03 | スミスクライン・ビーチャム・コーポレイション | トリアリールイミダゾール |
| AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| CA2422367C (en) | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| JP2004523474A (ja) | 2000-09-20 | 2004-08-05 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | チロシンキナーゼモジュレーターとしてのピラジン誘導体 |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| AU2004278382B2 (en) | 2003-09-30 | 2008-09-18 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| AU2007271964B2 (en) | 2006-07-14 | 2012-01-19 | Novartis Ag | Pyrimidine derivatives as ALK-5 inhibitors |
| ATE522249T1 (de) | 2007-07-26 | 2011-09-15 | Novartis Ag | Organische verbindungen |
| US8367662B2 (en) | 2007-10-17 | 2013-02-05 | Novartis Ag | Organic compounds |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| US8343966B2 (en) | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
| KR20100113557A (ko) | 2008-01-11 | 2010-10-21 | 노파르티스 아게 | 키나제 억제제로서의 피리미딘 |
| PL2307402T3 (pl) | 2008-04-29 | 2013-05-31 | Novartis Ag | Pochodne imidazo-pirydyny jako inhibitory kinazy podobnej do receptora aktywiny (ALK4 lub ALK5) |
| KR101938368B1 (ko) | 2011-07-13 | 2019-01-14 | 주식회사 티움바이오 | Alk5 및/또는 alk4 억제제로서의 2-피리딜-치환된 이미다졸 |
| WO2020012357A1 (en) * | 2018-07-10 | 2020-01-16 | Integral Biosciences Pvt. Ltd. | Heterocyclic compounds and methods of use |
-
2021
- 2021-07-14 JP JP2023502861A patent/JP2023533849A/ja active Pending
- 2021-07-14 EP EP21743186.5A patent/EP4182308A1/en active Pending
- 2021-07-14 KR KR1020237005127A patent/KR20230051500A/ko unknown
- 2021-07-14 BR BR112023000588A patent/BR112023000588A8/pt unknown
- 2021-07-14 AU AU2021307559A patent/AU2021307559A1/en active Pending
- 2021-07-14 CA CA3184990A patent/CA3184990A1/en active Pending
- 2021-07-14 US US18/014,764 patent/US20240018122A1/en active Pending
- 2021-07-14 CN CN202180061803.6A patent/CN116096719A/zh active Pending
- 2021-07-14 MX MX2023000521A patent/MX2023000521A/es unknown
- 2021-07-14 WO PCT/EP2021/069649 patent/WO2022013307A1/en unknown
- 2021-07-15 AR ARP210101996A patent/AR122986A1/es unknown
- 2021-07-15 TW TW110126103A patent/TW202216677A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021307559A1 (en) | 2023-02-16 |
| AR122986A1 (es) | 2022-10-19 |
| CN116096719A (zh) | 2023-05-09 |
| KR20230051500A (ko) | 2023-04-18 |
| TW202216677A (zh) | 2022-05-01 |
| MX2023000521A (es) | 2023-02-13 |
| BR112023000588A8 (pt) | 2023-05-09 |
| US20240018122A1 (en) | 2024-01-18 |
| EP4182308A1 (en) | 2023-05-24 |
| WO2022013307A1 (en) | 2022-01-20 |
| CA3184990A1 (en) | 2022-01-20 |
| JP2023533849A (ja) | 2023-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
| CL2021000387A1 (es) | Compuestos de anillo fusionado | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| AR113818A2 (es) | Pirazolo-quinazolinas como inhibidores de proteína quinasa | |
| BR112023000588A2 (pt) | Derivados de piridazina como inibidores de alk5 e/ou alk4 | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| NI201900099A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112013001088A2 (pt) | "derivados substituídos como inibidores a quinase de imidazoquinolina" | |
| BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
| BRPI0513858A (pt) | compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa | |
| NI201900098A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112012024017A2 (pt) | compostos derivados de triazina dissubstituída farmaceuticamemnte ativios, composição farmacêutica, método para a síntese destes e uso dos mesmos | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112016028642A2 (pt) | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. | |
| BR112022001862A2 (pt) | Compostos de piridopirimidinonila úteis como ativadores de célula t | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| NI201900119A (es) | Derivados de indolina sustitudos como inhibidores de la replicación vírica de dengue | |
| BRPI0409241A (pt) | compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso | |
| BRPI0611964A2 (pt) | moduladores de alquilquinolina e alquilquinazolina cinase | |
| BR112022012222A2 (pt) | Derivados de piperazina substituídos úteis como ativadores de células t | |
| BR112021023824A8 (pt) | Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
| BR112023002662A2 (pt) | Compostos de heteroarila substituída úteis como inibidores de tlr9 |